Apexian Pharmaceuticals, Inc.

Ocuphire Pharma, Inc. reported statistical significance for its eye drop candidate Nyxol in a second pivotal Phase III study in reversal of pharmacologically induced mydriasis (or pupil dilation). Ma

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Will Advance Yumanity Preclinical

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi

Below is Scrip’s monthly roundup, compiled by Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Janssen, Monash Univ.